Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDKRS3)

• Drug Name: Antistasin Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[1]

• Cross-matching ID: TTD Drug ID: DMDKRS3

Molecule-Related Drug Atlas

Drug(s) Targeting Coagulation factor Xa (F10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apixaban	DM89JLN	Thrombosis	DB61-GB90	Approved	[3]
Rivaroxaban	DMQMBZ1	Deep vein thrombosis	BD71	Approved	[4]
DU-176b	DMCIJBH	Atrial fibrillation	BC81.3	Approved	[5]
Emicizumab	DM0AQ83	Factor VIII deficiency	3B10	Approved	[6]
BETRIXABAN	DM2C4RF	Venous thromboembolism	BD72	Approved	[7]
Lmw heparin	DMJPD06	Coagulation defect	3B10.0	Approved	[8]
Nadroparin calcium	DMBNKST	Coagulation defect	3B10.0	Approved	[9]
Fondaparinux sodium	DMWS3FH	Deep vein thrombosis	BD71	Approved	[10]
Danaparoid	DM6CLBN	Deep venous clot	BD71	Approved	[11]
Coagulation Factor IX	DM8HBJI	Haemophilia B	3B11.0	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Coagulation factor Xa (F10)	TTCIHJA	FA10_HUMAN	Inhibitor	[2]

References

• [1] The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011 Jan;10(1):61-75.
• [2] Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
• [3] Pfizer. Product Development Pipeline. March 31 2009.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
• [6] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [7] Company report (Portola)
• [8] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [9] Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
• [10] Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
• [11] Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
• [12] Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.